Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving
Has the success of TAVR and other interventional techniques had a negative impact on surgical valve innovation? Two surgeons shared their concerns in a new commentary.
Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data
The new-look mitral valve is built using LifePolymer, a proprietary material that does not include any animal tissue. Both the frame and its leaflets are robotically generated to match each patient’s anatomy.
Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference
Cerebral embolic protection devices are proven to work. However, according to one cardiologist, they are still not consistently reducing stroke rates.
TTVR with Evoque system linked to positive real-world outcomes after 30 days
According to early real-world data, the FDA-approved Evoque TTVR device is associated with positive outcomes when used to treat severe tricuspid regurgitation.
A closer look at world’s first TAVR patient treated with new cerebral embolic protection device
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

The Corvia Atrial Shunt is designed to address elevated left atrial pressure (LAP) heart failure patients.

VIDEO: Overview of intra-atrial shunts to treat heart failure

Cardiologist Peter Fail, MD, discusses the idea of using shunts to form a passage that enables the left atrium to decompress at rest and during physical activity. The goal is to lower left atrial pressure in heart failure patients.

Radiation exposure during structural heart procedures much higher for echocardiographers than cardiologists

The new analysis focused on transcatheter edge-to-edge repair and left atrial appendage occlusion procedures.

VIDEO: The state of TAVR in 2022

Michael Mack, MD, a key pioneer in transcatheter aortic valve replacement (TAVR), explains the history of TAVR and where things are headed.

A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare

AFib patients more likely to be hospitalized for heart failure or bleeding following TAVR

The study, published in the American Journal of Cardiology, included data from more than 900 TAVR patients. Overall morality was 22.7% among patients with AFib and 14.4% among patients without AFib.

Tracking TAVR’s impact on gastrointestinal bleeding symptoms

TAVR patients with gastrointestinal bleeding (GIB) were linked to longer lengths of stay and a higher risk of acute kidney injury than patients without GIB.

Two examples of new left atrial appendage occluders (LAAO), the Conformal omn left and the Laminar on the right. evi Nair, MD, FACC, FHRS, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit. #TVT #TVT2020 #LAA #LAAO #EPeeps

VIDEO: Advances in left atrial appendage occlusion technology

Devi Nair, MD, director of cardiac electrophysiology at St. Bernard's Healthcare, Jonesboro, Arkansas, explains some of the recent advances in transcatheter left atrial appendage (LAA) occlusion technology at the 2022 Transcatheter Valve Therapeutics (TVT) Structural Heart Summit.

The Boston Scientific Acurate neo2,. Abbott Portico and the new Edwards Sapien X4 TAVR valves were hot topics of discussion at TCT 2022. #TVT #TVT22 #TVT2022

VIDEO: TAVR's long-term impact on patient care

One thing was clear at TVT 2022 in Chicago: TAVR's popularity over surgery is changing the way physicians think about patient care.

Links to all the late-breaking structural heart studies at TVT 2022

Here are links to more information for all the late-breaking presentations at the 2022 Transcatheter Valve Therapies (TVT) Structural Heart Summit.

Structural Heart Disease

At a crossroads: Surgical heart valve innovation slows as transcatheter treatments keep evolving

Polymer heart valve, the first of its kind to gain commercial approval, linked to positive 1-year data

Effective, but not worth the cost: CEPD use during TAVR fails to make a significant difference

TTVR with Evoque system linked to positive real-world outcomes after 30 days

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device